Upon joining the study, participants will be informed about the trial’s purpose, procedures, and potential risks and benefits. Consent will be obtained to ensure understanding and agreement to participate.

Participants will undergo an initial assessment to confirm eligibility. This includes a review of medical history and a physical examination. Imaging tests may be conducted to evaluate the current state of the endometrial cancer.

Participants will be randomly assigned to one of two groups: one receiving sacituzumab tirumotecan in combination with pembrolizumab, and the other receiving pembrolizumab alone. This process ensures that the study results are unbiased.

Participants will receive their assigned treatment. Pembrolizumab is administered as an intravenous infusion, which means it is given directly into a vein through a drip. The frequency and dosage will be determined by the study protocol and the healthcare team.

Throughout the study, participants will have regular check-ups to monitor their health and the effects of the treatment. This includes physical exams, blood tests, and imaging studies. The healthcare team will assess the cancer’s response to the treatment and any side effects experienced.

Once the treatment phase is completed, participants will undergo a final assessment. This will include a comprehensive evaluation of their health status and the effectiveness of the treatment.

After completing the treatment, participants will enter a follow-up phase. This involves periodic visits to monitor long-term health outcomes and any delayed side effects. The follow-up period is crucial for gathering data on the treatment’s long-term efficacy and safety.